Table 1. Patient and lesion characteristics and treatment details.
| Complete follow-up rate: 100% | N=66 |
|---|---|
| Observation period, months | 51 (7–103) |
| Age, years | 67 (45–82) |
| Sex | |
| Male | 61 (92) |
| Female | 5 (8) |
| Synchronous double cancers | 13 (20) |
| Head and neck cancer | 8 (12) |
| Gastric cancer | 5 (8) |
| Others | 3 (5) |
| Tumor location | |
| Cervix | 3 (5) |
| Upper thorax | 12 (18) |
| Middle thorax | 35 (52) |
| Lower thorax | 15 (23) |
| Abdomen | 1 (2) |
| Endoscopic resection | |
| EMRC | 12 (18) |
| ESD | 54 (82) |
| Vertical resection margin | |
| Positive | 5 (8) |
| Negative | 61 (92) |
| Pathological tumor depth | |
| Lamina propria mucosae | 5 (8) |
| Muscularis mucosae | 18 (27) |
| SM1 | 8 (12) |
| SM2 or deeper | 35 (53) |
| Lymphovascular involvement | |
| Positive | 36 (55) |
| Negative | 30 (45) |
| Chemotherapy | |
| Standard-dose CF | 58 (88) |
| Low-dose CF | 6 (9) |
| Others | 2 (3) |
| Radiation dose, Gy | |
| 40.0 | 55 (83) |
| 41.4 | 5 (8) |
| 50.0 | 4 (6) |
| 60.0 | 2 (3) |
CF, cisplatin and 5-fluorouracil; EMRC, endoscopic esophageal mucosal resection using a cap-fitted panendoscope; ESD: endoscopic submucosal dissection; SM1, submucosa up to 0.2 mm from muscularis mucosae; SM2, submucosa deeper than 0.2 mm from muscularis mucosae.
Data are presented as median (range) or n (%).